Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia.

ABSTRACT: Current treatments for acute myeloid leukemia (AML) are designed to target rapidly dividing blast populations with limited success in eradicating the functionally distinct leukemia stem cell (LSC) population, which is postulated to be responsible for disease resistance and relapse. We have previously reported high miR-126 expression levels to be associated with a LSC-gene expression profile. Therefore, we hypothesized that miR-126 contributes to 'stemness' and is a viable target for eliminating the LSC in AML. Here we first validate the clinical relevance of miR-126 expression in AML by showing that higher expression of this microRNA (miR) is associated with worse outcome in a large cohort of older (⩾60 years) cytogenetically normal AML patients treated with conventional chemotherapy. We t

SUBMITTER: Dorrance AM 

PROVIDER: S-EPMC4633325 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature